CurrentCareSourcePolicy N/A

Hemophilia Factor IX Products Utilization Management Medical Policy

CareSource utilization management policy describing prior authorization, coverage criteria, dosing, and prescribing requirements for recombinant and plasma‑derived Factor IX products for patients with Hemophilia B (and select other factor deficiencies). Applies to medical benefit coverage determinations.

Policy Summary

PayerCareSource

PolicyHemophilia Factor IX Products Utilization Management Medical Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateFeb 19, 2025

Key ActionObtain prior authorization and ensure the agent is prescribed by or in consultation with a hemophilia specialist when requesting Factor IX products.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

8Factor IX products listed (by name)

up to 100 IU/kgmax dosing per administration

up to 50 IU/kgprophylaxis dosing cited

1 in 30,000Hemophilia B prevalence

up to 5%reported inhibitor frequency

Policy Summary

PayerCareSource

PolicyHemophilia Factor IX Products Utilization Management Medical Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateFeb 19, 2025

Key ActionObtain prior authorization and ensure the agent is prescribed by or in consultation with a hemophilia specialist when requesting Factor IX products.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

FDA‑Approved Indication and Dosing

Covered when ALL of the following are met

FDA-approved hemophilia B indication: Agent is prescribed for Hemophilia B (FDA‑approved indication)

Prescribe by or in consultation with a hemophilia specialist; approve for 1 year when criteria met

Dosing regimens (select the regimen appropriate to the requested product): Approve one of the dosing regimens appropriate to the requested product: routine prophylaxis, on‑demand treatment and control of bleeding episodes, or perioperative management, with product‑specific frequency and duration limitsSee product‑specific dosing: routine prophylaxis up to 50–100 IU/kg (product dependent); on‑demand/perioperative up to 100 IU/kg with frequency/duration limits

For Alprolix, Idelvion, and Rebinyn follow their dosing options; for BeneFIX, Ixinity, and Rixubis follow their dosing options; approvals provided for specified frequencies and maximum durations

Other Uses with Supportive Evidence (Profilnine)

Covered when ALL of the following are met

Other supported uses for Profilnine: Profilnine is prescribed for Factor II deficiency or Factor X deficiency

Agent must be prescribed by or in consultation with a hemophilia specialist; approve for 1 year when criteria met; dosing mirrors recommended dosing in hemophilia B

Profilnine dosing options (per supported deficiency): Approve one of the following dosing approaches: A) Routine prophylaxis: up to 50 IU/kg IV no more frequently than twice weekly; OR B) On‑demand treatment and perioperative management: up to 100 IU/kg IV no more frequently than twice daily for up to 10 daysRoutine prophylaxis up to 50 IU/kg; on‑demand/perioperative up to 100 IU/kg for up to 10 days

Limited dosing information available for Factor X deficiency; recommended dosing references hemophilia B guidance

Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Requests for Factor IX products that do not meet the specified authorization criteria are not recommended for approval and may be denied. The Recommended Authorization Criteria will be updated as new published data become available.

Use of Factor IX products for indications outside the specified Recommended Authorization Criteria is considered not recommended for approval. Requests for off‑label or otherwise unsupported indications should be expected to be denied unless and until those uses are incorporated into the authorization criteria based on new evidence.

Dosing and Coding Limits

Dosing limits

Routine prophylaxis (product-dependent)Approve routine prophylaxis dosing up to 50–100 IU/kg IV with frequency per product (e.g., up to 50 IU/kg twice weekly for some products; up to 100 IU/kg no more frequently than once weekly for extended‑interval products)

On‑demand treatmentApprove on‑demand treatment and control of bleeding episodes up to 100 IU/kg IV per administration with product‑specific frequency limits (examples: no more frequently than once every 6 hours up to 10 days for some agents; no more frequently than once every 12–24 hours for others)

Perioperative managementApprove perioperative dosing up to 100 IU/kg IV per administration with product‑specific frequency and duration limits (examples: no more frequently than once every 24 hours for up to 10 days or per product labeling)

Frequency limits—extended vs standard half‑lifeExtended half‑life products may be dosed less frequently (e.g., up to once weekly at up to 100 IU/kg) while standard half‑life products have more frequent dosing limits (e.g., twice weekly or every 12–24 hours as specified)

Profilnine dosing alignmentProfilnine follows hemophilia B dosing: routine prophylaxis up to 50 IU/kg twice weekly; on‑demand/perioperative up to 100 IU/kg with frequency limits (e.g., twice daily up to 10 days)

Prescriber and Authorization Actions

Prior Authorization

Prior Authorization Recommended

Prior Authorization is recommended for medical benefit coverage of the listed Factor IX products (Alprolix, Idelvion, Rebinyn, BeneFIX, Ixinity, Rixubis, AlphaNine, and Profilnine). Approval is recommended only for patients who meet the Recommended Authorization Criteria and dosing specified for the indicated uses. Requests for doses or durations outside the established medical director or pharmacist authorization parameters may require additional review and documentation. Because of the specialized skills required for evaluation, diagnosis, monitoring of adverse events, and long-term efficacy, the agent must be prescribed by or in consultation with a physician who specializes in hemophilia or the condition being treated. All approvals are provided for the duration noted in the dosing/authorization details and may be extended if the patient continues to meet the criteria.

Affected agents: Alprolix; Idelvion; Rebinyn; BeneFIX; Ixinity; Rixubis; AlphaNine; Profilnine
Prior authorization: Recommended (medical benefit)
Prescriber requirement: Must be prescribed by or in consultation with a hemophilia specialist
Approval duration: As specified in dosing/authorization; extensions allowed if criteria continue to be met
Requests outside criteria or for doses/durations beyond established parameters may be denied or require Medical Director/Pharmacist review

Documentation Required

Provider Action Required

Provider action: Ensure documentation demonstrates the patient meets the Recommended Authorization Criteria for the requested agent and indication. Include clinical rationale, relevant laboratory or bleeding history, and the hemophilia specialist consultation or attestation in the submission. Requests lacking required documentation or for indications not listed in the criteria may be denied.

Include: diagnosis (Hemophilia B), treatment intent (routine prophylaxis, on-demand treatment, perioperative management), and proposed dosing regimen
Attach specialist consultation note or attestation when prescriber is not a hemophilia specialist
Document prior response to therapy or rationale for agent selection if switching or initiating prophylaxis

Note

Specialist Prescribing and Duration

Specialist prescribing and approval duration: The agent must be prescribed by or in consultation with a hemophilia specialist. Approvals are provided for the durations noted in the dosing regimens below (initial approval up to 1 year where indicated); continued approvals require ongoing documentation that the patient continues to meet the criteria and dosing limits.

Typical approval: up to 1 year when prescribed by/with hemophilia specialist
Continuation: eligible if patient continues to meet criteria and remains on recommended dosing
Dosing must follow the specific agent regimens outlined in the Recommended Authorization Criteria

Denial Risk

Coverage Not Recommended for Non‑Listed Indications

Denial risk: Coverage is not recommended for requests outside the Recommended Authorization Criteria. Requests for indications or dosing not specified in the criteria may be denied.

Non‑listed indications or unapproved uses for these Factor IX products are not recommended for coverage
Criteria will be updated as new published data become available

OpenPayer

Hemophilia Factor IX Products Utilization Management Medical Policy

Recommended Authorization Criteria

Dosing and Coding Limits

Prescriber and Authorization Actions

Clinical Background

Key Definitions